As­cle­tis Phar­ma scraps liv­er dis­ease pro­gram; An­oth­er re­verse merg­er

Last year
News Briefing

Ex­clu­sive: Backed with $350M, se­cre­tive start­up Met­sera jumps in­to the obe­si­ty race

Last year
Financing
Startups

Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Last year
Financing
Startups

Fi­bro­Gen eyes re­bound path with Ph1 ADC da­ta for prostate can­cer drug

Last year
R&D

Al­terome rais­es $132M to take next-gen can­cer drugs aimed at the 'un­drug­gable' in­to clin­ic

Last year
Financing
R&D

An­ti­body biotech Di­ag­o­nal Ther­a­peu­tics lands $128M to pur­sue rare dis­eases

Last year
Financing
Startups

Gen­mab fu­els AD­C­s' hot streak with $1.8B buy­out of Pro­found­Bio

Last year
Deals

Neu­roster­ix emerges with $63M to fol­low Karuna, Cerev­el

Last year
Financing
Startups

Ad­di­tion­al drug­mak­ers flag risks of work­ing with WuXi amid height­ened US scruti­ny

Last year
R&D
Pharma

Al­most all dos­es of Moun­jaro, Zep­bound in short sup­ply through Q2

Last year
Pharma
FDA+

US re­sponds to drug­mak­er­s' IRA coun­terof­fers as Medicare price ne­go­ti­a­tions con­tin­ue

Last year
Pharma

Ab­b­Vie com­mits to ‘mak­ing the big bets’ in new cor­po­rate cam­paign

Last year
Pharma
Marketing

Fed­er­al court gives Te­va and Vi­a­tris an­oth­er chance to in­val­i­date J&J's last patent for In­ve­ga Susten­na

Last year
Pharma
Law

Mar­ket­ingRx roundup: Pfiz­er switch­es up ad­ver­tis­ing du­ties; No­vo Nordisk’s Ozem­pic gets spoofed on SNL

Last year
Pharma
Marketing

Phar­ma is bet­ting big on con­nect­ing po­ten­tial pa­tients to its med­ica­tions. It's just the be­gin­ning

Last year
Pharma
Marketing

Zymeworks re­moves CFO; Gilead ex­tends Nurix deal

Last year
News Briefing

Acor­da files for bank­rupt­cy, agrees to sell MS drug and oth­er as­sets to Merz for $185M

Last year
Deals
Pharma

Ipsen boards ADC train in $900M pact with Sutro

Last year
Deals
Pharma

Grit­stone's Phase 2 can­cer vac­cine tri­al miss­es the mark, stock spi­rals down

Last year
R&D

Lon­za taps Siegfried leader Wolf­gang Wien­and as new CEO

Last year
People
Manufacturing

Three more I-Mab ex­ecs ex­it af­ter US/Chi­na op­er­a­tions split

Last year
People
China

Verve paus­es lead base edit­ing pro­gram af­ter safe­ty event, switch­es fo­cus to fol­low-up can­di­date near clin­ic

Last year
R&D
Cell/Gene Tx

Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Last year
Deals
R&D

Prov­i­dence spin­out Pra­ia Health rais­es $20M

Last year
Startups
Health Tech
First page Previous page 177178179180181182183 Next page Last page
A service from the Financial Times